Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

Las legislaturas publican los títulos, el historial y el texto oficial de los proyectos de ley en inglés, y los resúmenes provienen de fuentes en inglés, por eso aquí aparecen en inglés.

S. 43119.º Congreso

Skinny Labels, Big Savings Act

Leer el proyecto completo

Avance

  1. Presentado
  2. En comité Todavía no
  3. Aprobado por una cámara Todavía no
  4. Aprobado por el Congreso Todavía no
  5. Enviado al presidente Todavía no
  6. Se convirtió en ley Todavía no

En lenguaje sencillo

Skinny Labels, Big Savings Act

This bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs.

Under current law, the Food and Drug Administration (FDA) may approve generic and biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics.

The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act:

  • submitting or seeking approval of a skinny label for a generic or biosimilar drug;
  • promoting or commercially marketing a drug with skinny labeling approved by the FDA; or
  • describing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug.

The bill also applies the safe harbor to similar actions under the Public Health Service Act.

Resumen del Servicio de Investigación del Congreso (CRS), una oficina no partidista de la Biblioteca del Congreso. Versión resumida: Introduced in Senate.

Historial legislativo

  1. Senado

    Read twice and referred to the Committee on the Judiciary.

  2. Introduced in Senate